跳至主要内容
临床试验/NCT01670617
NCT01670617Unknown不适用

A Stratified, Post-Market Study of DeNovo NT for the Treatment of Femoral and Patellar Articular Cartilage Lesions of the Knee

Zimmer Orthobiologics, Inc.18 个研究点 分布在 2 个国家目标入组 90 人开始时间: 2012年3月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
入组人数
90
试验地点
18
主要终点
Improvement in KOOS scores

研究概览

简要总结

The purpose of this study is to evaluate the long-term relief of pain and return to function for patients receiving DeNovo NT for cartilage lesions in the knee. DeNovo NT is a marketed product and has been used in more than 7,500 patients over the last 7 years.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 55 Years(Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Voluntary signature of the IRB approved Informed Consent,
  • •Male or female subjects between the ages of 18 to 55 years,
  • •If female: Actively practicing a contraception method and willing to continue for a minimum of 1 year postoperatively, practicing abstinence and willing to continue for a minimum of 1 year postoperatively, or sterile
  • •One or two contained lesion(s) of the femur or patella ≥ ICRS Grade 3 or OCD lesions with healed bone base with no loss of bone greater than 6mm
  • •Has peripheral cartilage debridement to healthy cartilage that results in at least one lesion with an area of ≥ 2 cm2 and ≤ 7.5 cm2,
  • •Lesion(s) to be treated must be contained/shouldered > 70% of the periphery,
  • •Ligaments in the affected knee are stable,
  • •Ipsilateral knee compartment has intact menisci
  • •The contralateral knee is asymptomatic, stable, and fully functional,
  • •Is refractory to conservative non-surgical management or minimal surgical intervention and ≥ 3 months from the start of either treatment,
  • •Must record a response, at the preoperative study visit, of moderate to extreme pain for any one of the KOOS Pain Scale questions, P2 through P
  • •Must be physically and mentally willing and able, in the Investigator's opinion at the time of enrollment, to be compliant with the protocol

排除标准

  • •Clinical disease diagnosis of the indexed affected joint that includes
  • •Osteoarthritis or avascular necrosis,
  • •Rheumatoid arthritis, or history of septic or reactive arthritis,
  • •Gout or a history of gout or pseudogout in the affected knee,
  • •Bipolar articular cartilage involvement (or kissing lesions)
  • •Has more than two clinically relevant chondral lesion(s) on the index knee,
  • •Osteochondritis dissecans of the knee with significant bone loss
  • •Associated damage to the underlying subchondral bone requiring bone graft,
  • •Has well-defined subchondral cyst(s),
  • •Has current or impending subchondral avascular necrosis,
  • •History of secondary arthropathies (i.e., sickle cell disease, hemochromatosis, or autoimmune disease),
  • •Uncontrolled diabetes,
  • •Displays a high surgical risk due to unstable cardiac and/or pulmonary disease,
  • •Has HIV or other immunodeficient state
  • •Is at substantial risk for the need of organ transplantation
  • •Is pregnant or breast-feeding,
  • •Body Mass Index >35 (BMI=kg/m2),
  • •Is participating concurrently in another clinical trial
  • •Is receiving prescription pain medication other than NSAIDs or acetaminophen for conditions unrelated to the index knee condition, chronic use of anticoagulants, or taking corticosteroids,
  • •Has a neuromuscular, neurosensory, or musculoskeletal deficiency that limits the ability to perform objective functional assessment of either knee,
  • •Active joint infection or history of chronic joint infection at the surgical site,
  • •Prior total meniscectomy of either knee,
  • •Has severe patellofemoral malalignment/maltracking or patellar instability
  • •Radiographically has >5 degrees of malalignment
  • •Has received, within the past 3 months HA or cortisone injections in knee,
  • •Has undergone prior tendon repair, meniscus repair, ligament repair or distal realignment/osteotomy surgery in the index knee, < 6 months prior to surgery,
  • •Failed marrow stimulation or ACI treatment performed < 12-mo before baseline,
  • •Index knee has been surgically treated for cartilage repair with OATs, mosaicplasty or osteochondral allograft,
  • •Involves concomitant procedures in the affected knee with the exception of incidental loose body removal, debridement, synovectomy, retinacular release, and/or partial meniscectomy
  • •Has contraindications for Magnetic Resonance Imaging (MRI),
  • •Has an allergy to Polymyxin B sulfate or Bacitracin antibiotics,
  • •Is receiving workman's compensation or currently involved in litigation relating to the index knee

研究组 & 干预措施

DeNovo NT Graft

Other

DeNovo NT Graft stratified by lesion location - femur or patella

干预措施: Particulated Juvenile Articular Cartilage (Other)

结局指标

主要结局

Improvement in KOOS scores

时间窗: Between baseline and 24 months post surgery

Improvement in Knee Injury and Osteoarthritis Outcomes Survey (KOOS) scores

次要结局

  • Incidence and time to reoperation/revision(5 years)
  • Mean IKDC Knee Examination grades(Annually to 5 years post surgery)
  • MRI Evaluation(Preop, 12 Months and 24 Months post surgery)
  • Incidence of adverse events(Annually to 5 years post surgery)
  • X-ray Evaluation(Preop, 12 months and 24 months post surgery)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (18)

Loading locations...

相似试验